



August 08, 2022

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Dear Sir/ Madam,

Subject: Outcome of Board Meeting held on August 08, 2022 along with Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2022 and Press Release

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, *inter-alia*, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022. In this regard, kindly find enclosed the following:

1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2022.
2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2022.
3. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022.

The Board Meeting commenced at 07:00 p.m. and concluded at 09:10 p.m.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**

Krunal Shah

Company Secretary & Compliance Officer



Encl.: A/a

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Sequent Scientific Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sequent Scientific Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2022 attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I of the statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SRBC & CO LLP

Chartered Accountants

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- Fifteen subsidiaries, whose unaudited interim financial results include total revenues of Rs 24,971.51 lakhs, total net loss after tax of Rs. 1,782.73 lakhs and total comprehensive loss of Rs. 3,193.87 lakhs, for the quarter ended June 30, 2022, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
- Three subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs 242.57 lakhs total net loss after tax of Rs. 38.01 lakhs total comprehensive loss of Rs. 66.16 lakhs for the quarter ended June 30, 2022.

The unaudited interim financial results and other unaudited financial information of these subsidiaries, have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For **SRBC & CO LLP**

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per **Anil C Jobanputra**

Partner

Membership No.: 110759



UDIN: 22110759AONMMA5902

Place: Mumbai

Date: August 08, 2022

S R B C & CO LLP

Chartered Accountants

Annexure 1 to Auditor's report

Name of the Holding Company

1. Sequent Scientific Limited

Including its following wholly-owned subsidiaries:

2. Alivira Animal Health Limited, India
3. Sequent Research Limited

Including its following subsidiary:

4. Alivira Animal Health Limited, Ireland

Including its following subsidiaries and sub subsidiaries:

5. Comercial Vila Veterinaria De Lleida, S.L.
6. Laboratorios Karizoo, S.A.
7. Phytotherapic Solutions, S.L.
8. Vila Viña Participacions, S.L.
9. Alivira Saude Animal Ltda.
10. Aliviria Saude Animal Brasil Participacoes Ltda
11. Evanvet Distribuidora De Produtos Veterinarios Ltda
12. Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
13. Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
14. Laboratorios Karizoo, S.A. de C.V. (Mexico)
15. Alivira Animal Health UK Limited
16. Alivira France S.A.S
17. Alivira Italia S.R.L.
18. Alivira Animal Health USA LLC
19. Fendigo BV
20. Nourrie Saude e Nutricao Animal Ltda
21. N-Vet AB
22. Bremer Pharma GmbH
23. Fendigo SA



Sequent

Proven Ability In Life Sciences

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022

(₹ in Lakhs)

Sr. No.	Particulars	3 months ended 30-Jun-2022	Preceding 3 months ended 31-Mar-2022	Corresponding 3 months ended in previous period 30-Jun-2021	Previous year ended 31-Mar-2022
		Unaudited	Audited (Refer note 6)	Unaudited	Audited
I	Revenue from operations	34,132.10	38,370.90	32,050.90	141,281.60
II	Other income	87.90	377.00	267.00	1,084.50
III	Total income (I+II)	34,220.00	38,747.90	32,317.90	142,366.10
IV	Expenses				
	(a) Cost of materials consumed	17,912.80	18,076.00	16,878.50	67,052.20
	(b) Purchases of stock-in-trade	3,610.20	4,114.00	4,364.80	17,188.90
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,852.60)	(310.60)	(4,615.80)	(4,941.50)
	(d) Employee benefits expense	6,449.10	5,718.40	6,564.20	23,136.80
	(e) Finance costs	680.10	603.80	302.30	1,577.40
	(f) Depreciation and amortisation expenses	1,256.20	1,247.10	1,257.40	5,108.50
	(g) Other expenses	7,399.80	7,438.50	6,843.60	27,905.20
	(h) Net Monetary loss on Hyperinflation economy (Refer note 4)	401.20	-	-	-
	Total expenses (IV)	35,856.80	36,887.20	31,595.00	137,027.50
V	Profit / (loss) before tax and exceptional items (III-IV)	(1,636.80)	1,860.70	722.90	5,338.60
VI	Exceptional item (Refer note 5)	(319.80)	-	-	-
VII	Profit / (loss) before tax (V-VI)	(1,956.60)	1,860.70	722.90	5,338.60
VIII	Tax expense				
	(a) Current tax	(4.70)	1,047.00	488.10	2,572.80
	(b) Deferred tax	(511.30)	(270.30)	(30.00)	(537.20)
	(c) Adjustment of income tax pertaining to earlier period	-	80.40	-	(1,203.00)
	Total tax expense (VIII)	(516.00)	857.10	458.10	832.60
IX	Profit / (loss) after tax (VII-VIII)	(1,440.60)	1,003.60	264.80	4,506.00
X	Other comprehensive income / (expense)				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement gain / (loss) on defined benefits plans	10.50	(13.60)	2.80	1.40
	(b) Fair value gain / (loss) from investment in equity instruments	(1,724.40)	(1,951.70)	1,611.50	(4,006.70)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(2.90)	(1.60)	-	(1.60)
	(d) Deferred tax relating to items that will not be reclassified to profit or loss	201.60	216.60	(189.70)	451.20
	Items that will be reclassified to profit or loss				
	(a) Exchange differences on translation of foreign operations	(981.70)	(1,116.90)	(13.10)	(6,058.00)
	(b) Exchange differences on net investment in foreign operations	(718.70)	659.50	422.90	(1,252.30)
	Total other comprehensive income / (expense) (net of tax)	(3,215.60)	(2,207.70)	1,834.40	(10,866.00)
XI	Total comprehensive income / (expense), net of tax (IX+X)	(4,656.20)	(1,204.10)	2,099.20	(6,360.00)
	Profit / (loss) attributable to:				
	- Owners of the Company	(1,405.20)	896.20	87.30	4,125.10
	- Non-controlling interest	(35.40)	107.40	177.50	380.90
	Other comprehensive income / (expense) attributable to:				
	- Owners of the Company	(3,174.50)	(2,233.70)	1,758.90	(10,837.50)
	- Non-controlling interest	(41.10)	26.00	75.50	(28.50)
	Total comprehensive income / (expense) attributable to:				
	- Owners of the Company	(4,579.70)	(1,337.50)	1,846.20	(6,712.40)
	- Non-controlling interest	(76.50)	133.40	253.00	352.40
XII	Equity share capital (face value of ₹ 2 each)	4,988.70	4,967.40	4,967.40	4,967.40
XIII	Other equity				64,273.30
XIV	Earnings per equity share: (face value of ₹ 2 each) (not annualised)				
	(1) Basic (in ₹)	(0.57)	0.36	0.04	1.67
	(2) Diluted (in ₹)	(0.57)	0.36	0.04	1.65
	See accompanying notes to the unaudited consolidated financial results				



Sequent
Proven Ability In Life Sciences
SEQUENT SCIENTIFIC LIMITED

Notes:

1. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 08 August 2022.
2. As the Board of Directors monitors the business activity as a single segment viz. Pharmaceuticals, the financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments.

3. Information on Standalone Results:

(₹ in Lakhs)

Particulars	3 months ended 30-Jun-2022	Preceding 3 months ended 31-Mar-2022	Corresponding 3 months ended in previous period 30-Jun-2021	Previous year ended 31-Mar-2022
	Unaudited	Audited (Refer note 6)	Unaudited	Audited
Revenue from operations	6,486.00	6,367.30	4,665.70	21,962.60
Profit / (loss) before tax	115.50	803.70	(87.30)	1,569.00
Profit / (loss) after tax	84.00	664.84	(60.92)	1,479.90
Total comprehensive income / (expense), (net of tax)	(1,436.16)	(1,050.22)	1,362.78	(2,051.80)

4. The Group has applied IND AS 29 'Accounting for Hyperinflationary economies' on Turkish subsidiaries, since the Turkish Lira is a functional currency of these subsidiaries in Turkey which is a hyperinflationary economy. In preparing the consolidated financial results for the quarter, the non-monetary assets (includes goodwill, property, plant and equipment, etc), liabilities, owner's equity and statement of profit and loss of the aforesaid subsidiaries have been restated to the measuring unit current as on the reporting date by applying general price index of the Turkish economy. Considering that the presentation currency of consolidated financial results is INR, the restatement of comparative figures in consolidated financial results is not required. The impact of said restatements till 31 March 2022 of aforesaid subsidiaries has been considered in the opening retained earnings as at 01 April 2022.

5. Exceptional item represents estimated loss of book value of assets (Property, Plant and Equipment and Inventory) due to an incident of fire at Company's wholly owned subsidiary Alivira Animal Health Limited's (Alivira) API facility in Visakhapatnam on 07 May 2022. The manufacturing activities were temporarily disrupted and is currently operating under normalcy. Alivira has submitted the insurance claim and the same is under process with Insurance Company.

6. The above results includes the results for the quarter ended 31 March 2022 being the balancing figure between audited figures in respect of the full financial year and year to date published figures upto the third quarter of the previous financial year.

7. The previous period figures have been regrouped / reclassified wherever necessary to conform to current period's presentation.



For Sequent Scientific Limited

(Signature)
Rajaram Narayanan
Managing Director

Thane, 08 August 2022

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Sequent Scientific Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sequent Scientific Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S R B C & C O L L P**

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per **Anil C Jobanputra**

Partner

Membership No.: 110759

UDIN: 22110759AONLZX1302

Place: Mumbai

Date: August 08, 2022



Sequent

Proven Ability In Life Sciences

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022

(₹ in lakhs)

Sr. No.	Particulars	3 months ended 30-June-2022	Preceding 3 months ended 31-Mar-2022	Corresponding 3 months ended in previous period 30-Jun-2021	Previous year ended 31- Mar-2022
		Unaudited	Audited (Refer note 3)	Unaudited	Audited
I	Revenue from operations	6,486.00	6,367.30	4,665.70	21,962.60
II	Other income	588.00	577.20	576.30	2,764.30
III	Total income (I+II)	7,074.00	6,944.50	5,242.00	24,726.90
IV	Expenses				
	(a) Cost of materials consumed	4,025.90	4,042.11	3,150.50	12,400.68
	(b) Purchases of stock-in-trade	159.30	220.89	20.60	438.22
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(398.20)	(886.20)	(1,618.10)	(1,973.30)
	(d) Conversion and processing charges	697.90	776.10	1,159.30	3,757.50
	(e) Employee benefits expenses	952.20	449.40	1,128.30	2,738.20
	(f) Finance costs	35.40	60.80	16.70	161.00
	(g) Depreciation and amortisation expenses	238.10	234.10	230.80	959.30
	(h) Other expenses	1,247.90	1,243.60	1,241.20	4,676.30
	Total expenses (IV)	6,958.50	6,140.80	5,329.30	23,157.90
V	Profit / (loss) before tax (III-IV)	115.50	803.70	(87.30)	1,569.00
VI	Tax expense / (credit)				
	(a) Current tax	21.00	117.76	(15.78)	251.20
	(b) Deferred tax	10.50	30.40	(10.60)	52.00
	(c) Adjustment of income tax relating to earlier periods	-	(9.30)	-	(214.10)
	Total tax expense / (credit) (VI)	31.50	138.86	(26.38)	89.10
VII	Profit / (loss) after tax (V-VI)	84.00	664.84	(60.92)	1,479.90
VIII	Other comprehensive income / (expense)				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurements gain / (loss) on defined benefits plans	2.60	12.80	(1.10)	10.50
	(b) Fair value gain / (loss) from investment in equity instruments	(1,724.40)	(1,951.70)	1,611.50	(4,006.70)
	(c) Deferred tax relating to items that will not be reclassified to profit or loss	201.64	223.84	(186.70)	464.50
	Total other comprehensive income / (expense) (net of tax)	(1,520.16)	(1,715.06)	1,423.70	(3,531.70)
IX	Total comprehensive income / (expense), net of tax (VII+VIII)	(1,436.16)	(1,050.22)	1,362.78	(2,051.80)
X	Equity share capital (face value of ₹ 2 each)	4,988.70	4,967.40	4,967.40	4,967.40
XI	Other equity				99,141.41
XII	Earnings per equity share: (face value of ₹ 2 each) (not annualised)				
	(1) Basic (in ₹)	0.03	0.27	(0.02)	0.60
	(2) Diluted (in ₹)	0.03	0.27	(0.02)	0.59
	See accompanying notes to unaudited standalone financial results				



Sequent
Proven Ability In Life Sciences
SEQUENT SCIENTIFIC LIMITED


Notes:

- 1 The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 08 August 2022.
- 2 As the Board of Directors monitors the business activity as a single segment viz. Pharmaceuticals, the financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments.
- 3 The above results includes the results for the quarter ended 31 March 2022 being the balancing figure between audited figures in respect of the full financial year and year to date published figures upto the third quarter of the previous financial year.
- 4 The previous period figures have been regrouped/re-classified wherever necessary to conform to current period's presentation.

Thane, 08 August 2022



For Sequent Scientific Limited


Rajaram Narayanan
Managing Director



SeQuent Announces Q1 FY23 Results

Revenues at ₹ 3,413 Million, up by 6.5%, Latam and Formulations drive growth

Mumbai, August 08, 2022

SeQuent Scientific Limited (SeQuent) which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the period ended June 30th, 2022

Consolidated Financial Highlights

₹ in Millions

	Q1 FY23	Q1 FY22
Revenues	3,413	3,205
EBITDA (pre-ESOP)	201	358
<i>EBITDA (pre-ESOP) %</i>	5.9%	11.2%
EBITDA	110	202
<i>EBITDA %</i>	3.2%	6.3%

Detailed presentation on the performance forms part of this press release

Commenting on the Company's performance, **Rajaram Narayanan, Managing Director** stated "Our overall sales in Q1 FY 23 grew 6.5% compared to corresponding quarter last year, reflecting a strong, resilient performance in a challenging environment. We continue to progress on our strategy to build a sustainable global business in the area of animal health.

The Formulations segment grew 19.5% on constant currency basis, driven by a strong performance in Brazil, within the overall Emerging Markets region. The API business results however, are subdued owing to the exceptional impact of the fire incident at our Vizag plant in May, which hampered operations for a few days. We have now restored the operations in full and are geared to complete the backlog of shipments over the rest of the year.

The macro environment will remain challenging on account of volatility in currencies and sustained inflationary cost pressures in raw materials and utilities. However, with our concerted efforts in engaging our long-term partners, cautious price increases, and initiatives on cost management, we expect acceleration in the second half of this financial year.

We continue to invest in deepening our partnerships with global players, upgrading our manufacturing facilities, expanding the product pipeline and developing our people.”

Earnings Call with Investors

The Company will conduct an Earnings call at **11:00 AM IST on Aug 09, 2022**, where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263** or **+91 22 7115 8213**

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is India’s largest and amongst the ‘Top 20’ global animal health companies, backed by global investment firm ‘The Carlyle Group’ as promoter. The company generated annual revenues of ~\$ 180 Mn in FY22 with ~2/3rd revenues from regulated markets. The company has 9 manufacturing facilities across Europe, Turkey, Brazil & India with the Vizag site being India’s only USFDA approved dedicated veterinary API facility.

For details, feel free to contact:

Krunal Shah

Company Secretary Tel: +91 22 4111 4779

investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultants abhishek.s@sequent.in

orientcapital

A division of Link Intime India Pvt Ltd

Nachiket Kale

nachiket.kale@linkintime.co.in | +91 9920940808

Registered Office

301/A, ‘Dosti Pinnacle’, Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Websites: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

AHEAD

with purpose
and
confidence

Earnings Presentation

Q1 FY23

09th Aug 2022

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to, "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Q1 FY23 reflects a resilient performance in a challenging environment where our sales grew by 6.5% compared to Q1 FY22.

The Formulations business grew 19.5% on constant currency basis, driven by a strong performance in Latam within the overall Emerging Markets region. The API business was however subdued owing to the exceptional impact of a fire incident at our Vizag plant in May 2022, when the operations were hampered for a few days. The operations are now fully functional, and we are geared to complete the backlog of shipments over the rest of the year. We are also pleased to report that our Mahad facility received ISO certifications for Environment, Health & Safety.

The macro environment continues to remain challenging on account of volatility in currencies and sustained inflationary cost pressures in raw materials and utilities. However, with our concerted efforts in engaging long-term partners, undertaking cautious price increases, and driving cost management initiatives, we expect stronger growth in the second half of this financial year.

We will pursue with our commitment to deepen partnerships with global players, upgrading our manufacturing facilities, expanding product pipeline and harnessing talent to deliver on our strategy of building a sustainable global business in the area of animal health.

Rajaram Narayanan, Managing Director

BUSINESS

- Overall Q1 FY23 Revenues at ~₹ 3.41 Bn; + 6.5% growth (+12.8% in cc)
- Formulations revenues at ~₹ 2.45 Bn, +19.5% (cc)
 - Latam drives strong growth
 - India maintains momentum in a challenging environment
 - Europe & Turkey grew in cc terms
- API revenues at ₹ 888 Mn, declined by 5.9% (cc) – impacted by supply disruption due to a fire incident


MANUFACTURING

- Vizag API facility operations impacted by fire incident in May
- Significant investments being made to meet new business opportunities and standards
- Mahad site ISO certified from TÜV NORD CERT GmbH

FINANCE

- Completed Nourrie's integration in Brazil
- Stable Gross margin in sequential quarters
- Inflationary input cost pressures continue
- Structured initiatives for cost management and de-risking currency volatility

Performance Overview




Q1 FY23 : Sustained growth, Formulations leading the way

All values in ₹ Mn

Revenue Distribution	Q1 FY23	Q1 FY22	YoY Gr%	YoY Gr% (In cc)
Formulations	2,448	2,269	7.9%	19.5%
Europe	1,036	1,053	(1.6%)	6.5%
Emerging Markets (EMs)	1,175	989	18.8%	28.3%
LATAM	674	510	32.2%	17.3%
Turkey	311	291	7.0%	90.9%
Other EMs	190	188	0.7%	6.3%
India	237	227	4.7%	4.7%
APIs	888	911	(2.5%)	(5.9%)
Other Sales	47	26	NM	NM
Global Sales	3,383	3,205	5.6%	12.8%
Adjustment* – Ind AS 29	30	-	-	-
Reported Sales	3,413	3,205	6.5%	12.8%

- ❖ Overall business grows by 12.8% cc during Q1
 - ❖ Formulations maintains growth momentum with 19.5% cc growth
 - ❖ Europe and Turkey businesses grow at cc, however impacted by currency depreciations, India sustains growth despite challenging environment
 - ❖ Latam performs exceptionally well leading Emerging Markets (EMs) overall with +17% cc growth in Q1
 - ❖ API performance subdued, impacted by Vizag fire; down time leveraged to strategically upgrade processes and infrastructure

Business Review



Formulations : Growth momentum continues

Key Updates

- ❖ Q1 revenues at ₹ 2.45 Bn, constant currency growth in all geographies and markets
- ❖ Demand stable, however input cost pressures and supply chain weaknesses continue to impact
- ❖ Latam outperforms, driving overall EMs growth; expansion continues with Nourrie's integration
- ❖ Europe, Turkey and Other EMs – all grow in cc terms, however impacted by currency volatilities
- ❖ India business performed well across Cattle & Poultry segments despite tough market conditions

Revenues

All values in ₹ Mn



cc- Constant Currency

FDFs

1000+

Manufacturing facilities

6

R&D Centres

5

Countries with marketing presence

80


API : Impacted by one-off incident, but quick recovery underway

Key Updates Highlights

- ❖ API sales declined to ₹ 888 Mn, exceptional one-off of fire incident at Vizag facility in May; Operations resumed with full normalcy
- ❖ Significant initiatives made in building resilience in infrastructure and processes and preparing for new businesses. CDMO business progression on track for the year
- ❖ Submitted 1 VMF filing – Total 25 USVMF filings, 11 CEP approvals
- ❖ Mahad site ISO certified from TÜV Nord for 14001 – Environment & 45001 – Health & Safety

Revenues

All values in ₹ Mn




Commercial APIs 33

Manufacturing facilities 3

R&D Centre 1

Asset turnover ratio 2.0x

Financials



Consolidated Financials

Particulars	Q1 FY23*	Q4 FY22	Q1 FY22	FY22
	Unaudited	Audited	Unaudited	Audited
Revenue from Operations	3,413	3,837	3,205	14,128
Material Consumption	(1,967)	(2,188)	(1,663)	(7,930)
Gross Margin	1,446	1,649	1,542	6,198
%	42.4%	43.0%	48.1%	43.9%
Employee Benefits	(554)	(519)	(499)	(1,985)
Operating Expenses	(691)	(744)	(684)	(2,791)
EBITDA (pre ESOP)	201	386	358	1,423
%	5.9%	10.1%	11.2%	10.1%
ESOP cost	(91)	(53)	(156)	(329)
EBITDA	110	333	202	1,094
%	3.2%	8.7%	6.3%	7.7%
Exceptional Items	(32)	-	-	-
Ind AS 29 Adjustment	(40)	-	-	-
Exchange Gain / (Loss)	(49)	23	12	63
Other Income	9	15	15	45
Finance Cost	(68)	(60)	(30)	(158)
Depreciation	(126)	(125)	(126)	(511)
Earnings Before Tax	(196)	186	72	534
Taxes	52	(86)	(46)	(82)
Earnings After Tax	(144)	100	26	452
Minority Interest	(4)	10	18	38
Earnings after Minority Interest	(141)	90	9	414

All values in ₹ Mn

- ❖ Exceptional Items related to Vizag fire loss on account of Inventory & Fixed assets; Insurance claim under progress

*Q1 FY23 reported numbers are after taking impact of hyperinflation accounting in Turkey financials as per IndAS 29

Key Balance Sheet Items

All values in ₹ Mn

Particulars	Jun-22*	Mar-22
Shareholders Funds	6,548	6,924
Minority Interest	466	480
Net Debt	2,918	2,542
Investments	179	368
Tangible Assets	3,251	3,253
Intangible Assets	2,311	2,413
Working Capital	4,216	4,222
Put / Buyout Liabilities	-	159

Balance Sheet Highlights

- ❖ Decrease in Shareholders fund owing to loss during the quarter, MTM impact of investment & translation impact
- ❖ Rise in net debt on account of Nourrie Acquisition – ₹ 376 Mn
- ❖ Inventory build-up for future sales plan
- ❖ Buyout Liabilities of ₹ 159 Mn paid on account of Nourrie acquisition

For details, feel free to contact:

Krunal Shah

Company Secretary

+91 22 4111 4779

✉ investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultant

✉ abhishek.s@sequent.in

Nachiket Kale

Investor Relations Advisor

+91 9920940808


✉ nachiket.kale@linkintime.co.in

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

Websites: www.sequent.in, www.alivira.co | **CIN:** L99999MH1985PLC036685 | **BSE Code:**512529 | **NSE:** SEQUENT | **ISIN:**

INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



Thank You